FI107879B - Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi - Google Patents
Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi Download PDFInfo
- Publication number
- FI107879B FI107879B FI941133A FI941133A FI107879B FI 107879 B FI107879 B FI 107879B FI 941133 A FI941133 A FI 941133A FI 941133 A FI941133 A FI 941133A FI 107879 B FI107879 B FI 107879B
- Authority
- FI
- Finland
- Prior art keywords
- thymosin
- interferon
- patients
- hepatitis
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title claims description 4
- 208000005176 Hepatitis C Diseases 0.000 title description 16
- 108010046075 Thymosin Proteins 0.000 claims abstract description 36
- 102000007501 Thymosin Human genes 0.000 claims abstract description 36
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims abstract description 27
- 108010078233 Thymalfasin Proteins 0.000 claims abstract description 11
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims abstract description 11
- 102000014150 Interferons Human genes 0.000 claims description 33
- 108010050904 Interferons Proteins 0.000 claims description 33
- 241000711549 Hepacivirus C Species 0.000 claims description 26
- 229940079322 interferon Drugs 0.000 claims description 26
- 108010047761 Interferon-alpha Proteins 0.000 claims description 15
- 102000006992 Interferon-alpha Human genes 0.000 claims description 15
- 210000000987 immune system Anatomy 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 108700016958 thymosin fraction 5 Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 abstract description 2
- 229960004231 thymalfasin Drugs 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 41
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 28
- 108010082126 Alanine transaminase Proteins 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 20
- 230000004044 response Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 208000006454 hepatitis Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 8
- 229940047124 interferons Drugs 0.000 description 8
- 238000012317 liver biopsy Methods 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 208000010710 hepatitis C virus infection Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- -1 TF-5 Chemical compound 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000008935 histological improvement Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000009594 Animal Hepatitis Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000002809 confirmatory assay Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75954491A | 1991-09-13 | 1991-09-13 | |
| US75954491 | 1991-09-13 | ||
| US9207556 | 1992-09-08 | ||
| PCT/US1992/007556 WO1993005806A1 (en) | 1991-09-13 | 1992-09-08 | Composition and method of treating hepatitis c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI941133A0 FI941133A0 (fi) | 1994-03-10 |
| FI941133L FI941133L (fi) | 1994-03-10 |
| FI107879B true FI107879B (fi) | 2001-10-31 |
Family
ID=25056052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI941133A FI107879B (fi) | 1991-09-13 | 1994-03-10 | Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6001799A (cs) |
| EP (1) | EP0603305B1 (cs) |
| JP (1) | JP3228512B2 (cs) |
| KR (1) | KR100254082B1 (cs) |
| AT (1) | ATE152914T1 (cs) |
| AU (1) | AU667327B2 (cs) |
| CA (1) | CA2119006C (cs) |
| CZ (1) | CZ286827B6 (cs) |
| DE (1) | DE69219782T2 (cs) |
| DK (1) | DK0603305T3 (cs) |
| ES (1) | ES2103966T3 (cs) |
| FI (1) | FI107879B (cs) |
| GR (1) | GR3024025T3 (cs) |
| HK (1) | HK1021687A1 (cs) |
| HU (1) | HU221006B1 (cs) |
| MX (1) | MX9205240A (cs) |
| NO (1) | NO941310L (cs) |
| RO (1) | RO111991B1 (cs) |
| RU (1) | RU2104010C1 (cs) |
| SG (1) | SG64897A1 (cs) |
| TW (1) | TW224053B (cs) |
| WO (1) | WO1993005806A1 (cs) |
| ZA (1) | ZA926964B (cs) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW224053B (cs) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| EP0728010A4 (en) * | 1992-02-06 | 1997-10-01 | Sciclone Pharmaceuticals | METHOD FOR TREATING HEPATITIS B CARRIERS WITH A MINOR DISEASE |
| AU751199B2 (en) * | 1992-07-13 | 2002-08-08 | Government Of The United States Of America As Represented By The Secretary Of The Army | Composition and method of treating hepatitis B |
| WO1994001125A1 (en) * | 1992-07-13 | 1994-01-20 | Sherman Kenneth E | Composition and method of treating hepatitis b |
| CN1072961C (zh) * | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
| US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| US5468729A (en) * | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
| EP0731710B1 (en) * | 1993-11-05 | 2003-05-14 | Alpha 1 Biomedicals, Inc. | Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease |
| JP3837769B2 (ja) * | 1995-06-12 | 2006-10-25 | 大塚製薬株式会社 | 抗ウイルス剤 |
| AU722987B2 (en) * | 1996-02-28 | 2000-08-17 | Unihart Corporation | Pharmaceutical compositions comprising natural human alpha-interferon |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
| AU2001283536B2 (en) * | 2000-08-07 | 2005-09-01 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| WO2002044717A1 (en) * | 2000-12-01 | 2002-06-06 | Cornell Research Foundation | Animal model for flaviviridae infection |
| RU2211703C2 (ru) * | 2001-06-08 | 2003-09-10 | ООО НТЦ "Юпитер-2" | Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием |
| US7138376B2 (en) * | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| WO2003030613A2 (en) * | 2001-10-05 | 2003-04-17 | Intermune, Inc. | Methods of treating liver fibrosis and hepatitis c virus infection |
| CN1269524C (zh) * | 2001-10-26 | 2006-08-16 | 罗得岛医院 | 胸腺素强化的遗传免疫方法 |
| UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| AU2003217402A1 (en) * | 2002-02-14 | 2003-09-04 | Pharmasset Inc | Modified fluorinated nucleoside analogues |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| AP2005003213A0 (en) | 2002-06-28 | 2005-03-31 | Univ Cagliari | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. |
| EP2799442A1 (en) | 2002-06-28 | 2014-11-05 | IDENIX Pharmaceuticals, Inc. | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| PL377287A1 (pl) | 2002-12-12 | 2006-01-23 | Idenix (Cayman) Limited | Sposób wytwarzania 2'-rozgałęzionych nukleozydów |
| GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| JP4149296B2 (ja) * | 2003-03-26 | 2008-09-10 | 株式会社ルネサステクノロジ | 半導体記憶装置 |
| WO2004087067A2 (en) | 2003-03-28 | 2004-10-14 | Sciclone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
| ES2345552T3 (es) * | 2003-03-28 | 2010-09-27 | Sciclone Pharmaceuticals, Inc. | Tratamiento de infecciones por aspergillus con timosina alfa 1. |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| JP4958158B2 (ja) | 2003-05-30 | 2012-06-20 | ギリアド ファーマセット エルエルシー | 修飾されたフッ化ヌクレオシド類似体 |
| PT1658302E (pt) | 2003-07-25 | 2010-10-25 | Centre Nat Rech Scient | Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c |
| WO2005021007A1 (en) * | 2003-08-28 | 2005-03-10 | Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' | Prevention and treatment of viral hepatitis c |
| CN1980657A (zh) | 2004-05-05 | 2007-06-13 | 耶鲁大学 | 新颖的抗病毒赛菊宁黄质类似物 |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| SG192409A1 (en) | 2004-09-14 | 2013-08-30 | Gilead Pharmasset Llc | 2-deoxy-2-fluoro-2-c-methyl-ribono lactones, and preparation thereof and 1,3-dioxolanes |
| JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
| CA2634749C (en) | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| JP5441685B2 (ja) * | 2006-05-02 | 2014-03-12 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用 |
| ES2288118B1 (es) * | 2006-05-10 | 2008-11-01 | Bcn Peptides, S.A. | Procedimiento para sintetizar timosinas. |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| WO2010042697A1 (en) * | 2008-10-08 | 2010-04-15 | University Of Miami | Regulation of lymphocytes and uses therefor |
| KR20110099138A (ko) | 2008-12-23 | 2011-09-06 | 파마셋 인코포레이티드 | 뉴클레오시드 포스포르아미데이트 |
| EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
| NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
| US8716012B2 (en) | 2009-05-08 | 2014-05-06 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| UA122959C2 (uk) | 2010-03-31 | 2021-01-27 | Гайлід Фармассет Елелсі | Нуклеозидфосфорамідати |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US8809354B2 (en) | 2011-12-31 | 2014-08-19 | Sheikh Riazuddin | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
| CN103800293B (zh) * | 2012-11-09 | 2015-10-21 | 长春海悦药业有限公司 | 一种含有胸腺法新的药物组合物及其制剂 |
| EP3038601B1 (en) | 2013-08-27 | 2020-04-08 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1216056B (it) * | 1988-03-11 | 1990-02-22 | Sclavo Spa | Composizioni farmaceutiche contenenti timosina alfa 1. |
| US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
| TW224053B (cs) * | 1991-09-13 | 1994-05-21 | Paul B Chretien |
-
1992
- 1992-03-16 TW TW081101971A patent/TW224053B/zh active
- 1992-09-08 RO RO94-00409A patent/RO111991B1/ro unknown
- 1992-09-08 AT AT92919977T patent/ATE152914T1/de active
- 1992-09-08 HK HK98105712A patent/HK1021687A1/en not_active IP Right Cessation
- 1992-09-08 HU HU9400758A patent/HU221006B1/hu not_active IP Right Cessation
- 1992-09-08 EP EP92919977A patent/EP0603305B1/en not_active Expired - Lifetime
- 1992-09-08 SG SG1996006295A patent/SG64897A1/en unknown
- 1992-09-08 ES ES92919977T patent/ES2103966T3/es not_active Expired - Lifetime
- 1992-09-08 CZ CZ1994551A patent/CZ286827B6/cs not_active IP Right Cessation
- 1992-09-08 CA CA002119006A patent/CA2119006C/en not_active Expired - Lifetime
- 1992-09-08 JP JP50608393A patent/JP3228512B2/ja not_active Expired - Fee Related
- 1992-09-08 AU AU26447/92A patent/AU667327B2/en not_active Ceased
- 1992-09-08 WO PCT/US1992/007556 patent/WO1993005806A1/en active IP Right Grant
- 1992-09-08 DK DK92919977.6T patent/DK0603305T3/da active
- 1992-09-08 RU RU94022480A patent/RU2104010C1/ru active
- 1992-09-08 KR KR1019940700603A patent/KR100254082B1/ko not_active Expired - Fee Related
- 1992-09-08 DE DE69219782T patent/DE69219782T2/de not_active Expired - Lifetime
- 1992-09-11 ZA ZA926964A patent/ZA926964B/xx unknown
- 1992-09-14 MX MX9205240A patent/MX9205240A/es not_active IP Right Cessation
-
1993
- 1993-03-05 US US08/027,500 patent/US6001799A/en not_active Expired - Lifetime
- 1993-11-04 US US08/145,660 patent/US5849696A/en not_active Expired - Lifetime
-
1994
- 1994-03-10 FI FI941133A patent/FI107879B/fi not_active IP Right Cessation
- 1994-04-12 NO NO941310A patent/NO941310L/no unknown
-
1997
- 1997-07-09 GR GR970401680T patent/GR3024025T3/el unknown
-
2007
- 2007-05-11 US US11/801,834 patent/US20070218033A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI107879B (fi) | Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi | |
| HK1021687B (en) | Use of a thymosin in the treatment of hepatitis c | |
| CA2236591C (en) | Continuous low-dose cytokine infusion therapy | |
| Lok et al. | Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection | |
| Grüngreiff et al. | Serum concentrations of sIL-2R, IL-6, TGF-β1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha | |
| Pockros | Developments in the treatment of chronic hepatitis C | |
| Artillo et al. | Double‐blind, randomized controlled trial of interleukin‐2 treatment of chronic hepatitis B | |
| Douglas et al. | Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM | |
| Ruiz-Moreno et al. | Levamisole and interferon in children with chronic hepatitis B | |
| EP0687181B1 (en) | Use of thymosin for treating hepatitis c in non-responders to interferon treatment | |
| WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
| Kagawa et al. | A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C | |
| Moskovitz et al. | High Dose Consensus Interferon in Nonresponders to Interferon Alpha‐2B and Ribavirin with Chronic Hepatitis C | |
| JPH07258109A (ja) | Ｃ型肝炎の処置法および処置用組成物 | |
| Hwang et al. | A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C | |
| Bosch et al. | Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole | |
| WO1993020835A1 (en) | Treatment of hepatitis with gm-csf | |
| Pockros | Current status of immunomodulatory therapies in HCV infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: ALPHA 1 BIOMEDICALS, INC. |
|
| GB | Transfer or assigment of application |
Owner name: ALPHA 1 BIOMEDICALS, INC. |
|
| MM | Patent lapsed |